
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc. is projected to experience significant revenue growth driven by its Signatera test, with a notable increase in clinical and biopharmaceutical use anticipated this year. The company is also pursuing expanded reimbursement coverage for Signatera across additional cancer types, which is expected to enhance average selling prices, gross margins, and operating cash flow. In the most recent quarter, Natera reported a remarkable revenue beat of approximately $80 million and raised its 2025 revenue guidance by $160 million, highlighting strong market demand and operational performance.
Bears say
Natera Inc faces pressure on its profit margins due to anticipated reductions in in-network pricing as it expands its target market, which may include more average-risk patients. The company is also at risk of significant declines in stock value should it encounter negative developments related to regulatory issues, reimbursement challenges, or delays in product launches, all of which could impact its financial performance. Furthermore, competitive pressures from other diagnostic companies, like Guardant Health, highlight the importance of reimbursement coverage and compelling clinical data, which are crucial for Natera's growth and market expansion.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares